MAPT and Cognitive impairment: Although plasma p‐tau217 levels accurately predict tau pathology in amyloid‐positive individuals without cognitive impairment,27 further studies are needed to clarify the specificity of elevated plasma p‐tau181 (and other isoforms) for AD over other causes of neurodegeneration in the context of amyloid accumulation.